Novartis Reports Results of QMF149 in P-III PALLADIUM Study for Patients with Uncontrolled Asthma

 Novartis Reports Results of QMF149 in P-III PALLADIUM Study for Patients with Uncontrolled Asthma

Novartis Reports Results of QMF149 in P-III PALLADIUM Study for Patients with Uncontrolled Asthma

Shots:

  • The P-III PALLADIUM study involves assessing of QMF149 [indacaterol acetate + mometasone furoate (IND/MF)] vs mometasone furoate (MF) as monothx. in 2,216 asthma patients with medium or high dose ICS or low dose ICS/LABA use 3mos. prior to screening, a pre-bronchodilator FEV1 of ≥50%, >80% of the predicted normal value for the patient and an ACQ-7 score >1.5
  • The P-III PALLADIUM study resulted in meeting its 1EPs & 2EPs i.e, improvement in FEV1 @26wks.; improvement in Asthma ACQ-7 @26wks., improvement in peak expiratory flow, exacerbation rates, rescue medication. Additionally, QMF149 showed improvement in lung function when compared with LABA/ICS
  • QMF149 (qd) is an investigational inhaled combination therapy of IND (a LABA [long-acting beta agonist]) and glycopyrronium bromide (a LAMA [long-acting muscarinic receptor antagonist]) with an anti-inflammatory action of MF (high- or medium-dose ICS [inhaled corticosteroid]), delivered via Breezhaler device

Click here to­ read full press release/ article | Ref: Novartis | Image: Wall Street Journal

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post